Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis

Does a combination of Arimidex and Zoladex make endometriomas shrink and how is the following IVF outcome

Completed

Looking for future studies?

Key information

Conditions

Endometriosis Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Urogenital Diseases

Age range

20 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

The Fertility Clinic, Copenhagen University Hospital, Rigshospitalet

Copenhagen, Copenhagen East, 2100, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Endometrioma(s)with a size of 20-70 mm, persisted for at least 3 cycles
Couples with indication and wish for IVF/ICSI
Age of women: 20-40 years
Regular menstrual cycle within normal range (21-35 days)
Body Mass Index (BMI): 18-30 kg/m2

Exclusion criteria

History with osteoporosis, liver-, kidney- or heart disease or thromboembolic disease
Treatment of endometriosis with GnRH agonist during the last 3 month

Treatment and study plan

Combined treatment with Arimidex and Zoladex before IVF

Drug

Primary outcomes

size of endometriomas after 2½ month of combined downregulation

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Important dates

Study start: 2005
First posted: Feb 3, 2006
Registry last updated: Apr 23, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed